CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Big Upside Potential

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Big Upside Potential CymaBay TherapeuticsTicker: CymaBay TherapeuticsPrice: $3.39 Business Summary CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent […]